GW501516 (Cardarine) – Powder, 1000mg

GW501516 (Cardarine) – Powder, 1000mg


Bulk Pricing
1 2-4 5-9 10-19 20-49 50+
US$40.00 US$36.00 US$32.00 US$28.00 US$24.00 US$20.00

Frequently Purchased With

Read the Specification Before Buying:

Application PPARδ receptor agonist
CAS 317318-70-0
Molar Mass 453.498 g/mol
 Chemical Formula C21H18F3NO3S2
Chemical Name {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid
Synonyms GW501516, Cardarine, Endurobol, GSK-516
Storage Room temperature
Solubility PEG, Ethanol
Organoleptic Profile White to beige fine powder
Physical Form Solid
Terms The products we offer are intended for laboratory research use only.
Please familiarize yourself with our Terms & Conditions prior to ordering.
Additional Notes This compound was withdrawn from clinical trials due to promotion of carcinogenesis.


  1. “GW501516 GlaxoSmithKline, Ligand milestone payment.”. R & D Focus Drug News. 28 June 2004.
  2. Wolf G (November 2003). “The function of the nuclear receptor peroxisome proliferator-activated receptor delta in energy homeostasis”.Nutr. Rev. 61 (11): 387–90. doi:10.1301/nr.2003.nov.387-390.PMID 14677574.
  3. Oliver WR, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM (April 2001). “A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport”. Proc. Natl. Acad. Sci. U.S.A.98 (9): 5306–11. doi:10.1073/pnas.091021198. PMC 33205.PMID 11309497.
  4. “GW501516 Glaxo Wellcome phase change I, UK”. R & D Focus Drug News. 20 November 2000.
  5. “GW501516 GlaxoSmithKline phase change II, UK”. R & D Focus Drug News. 25 February 2002.
  6. Barish GD, Narkar VA, Evans RM (March 2006). “PPAR delta: a dagger in the heart of the metabolic syndrome”. J. Clin. Invest. 116(3): 590–7. doi:10.1172/JCI27955. PMC 1386117.PMID 16511591.
  7. Uwe Dressel, Tamara L. Allen, Jyotsna B. Pippal, Paul R. Rohde, Patrick Lau, and George E. O. Musc (2003). “The Peroxisome Proliferator-Activated Receptor β/δ Agonist, GW501516, Regulates the Expression of Genes Involved in Lipid Catabolism and Energy Uncoupling in Skeletal Muscle Cells”. Molecular Endocrinology 17(12): 2477–93. doi:10.1210/me.2003-0151. PMID 14525954.
  8. Billin AN (October 2008). “PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home”.Expert Opin Investig Drugs 17 (10): 1465–71.doi:10.1517/13543784.17.10.1465. PMID 18808307.
  9. Sahebkar A, Chew GT, Watts GF (2014). “New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease”. Expert Opin Pharmacother 15 (4): 493–503.doi:10.1517/14656566.2014.876992. PMID 24428677. Despite these promising early results, the further investigation and development of GW501516 was discontinued after observations in animal studies of its association with the rapid induction of cancers in several organs (liver, stomach, tongue, skin, bladder, ovaries, womb and testes
  10. Geiger LE, Dunsford WS, Lewis DJ, Brennan C, Liu KC, Newsholme SJ (2009). PS 895 – Rat carcinogenicity study with GW501516, a PPAR delta agonist (PDF). 48th Annual Meeting of the Society of Toxicology. Baltimore: Society of Toxicology. p. 105. Archived from the original (PDF) on 2015-05-04.
  11. Newsholme SJ, Dunsford WS, Brodie T, Brennan C, Brown M, Geiger LE (2009). PS 896 – Mouse carcinogenicity study with GW501516, a PPAR delta agonist. (PDF). 48th Annual Meeting of the Society of Toxicology. Baltimore: Society of Toxicology. p. 105. Archived from the original (PDF) on 2015-05-04.
  12. Sprecher DL (December 2007). “Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta”. Am. J. Cardiol. 100 (11 A): n20–4. doi:10.1016/j.amjcard.2007.08.009. PMID 18047848.